A multi-epitope self-amplifying mRNA SARS-CoV-2 vaccine design using a reverse vaccinology approach
Research in Pharmaceutical Sciences · 2024-09 · 19 (5) · 520-548
DOI: 10.4103/rps.rps_91_23 ↗Kurz gefasst
Fachartikel in der Zeitschrift Research in Pharmaceutical Sciences, online erschienen am 22.10.2024. Verfasst von Brigitta Claudia und 2 weiteren Autor:innen. Beteiligte Einrichtung: School of Life Sciences and Technology, Institut Teknologi Bandung, Jalan Ganesa 10, Bandung 40132, Indonesia. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 58 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Background and purpose: Massive vaccine distribution is a crucial step to prevent the spread of SARS-CoV2 as the causative agent of COVID-19. This research aimed to design the multi-epitope self-amplifying mRNA (saRNA) vaccine from the spike and nucleocapsid proteins of SARS-CoV2. Experimental approach: Commonly distributed constructions class I and II alleles of the Indonesian population were used to determine peptide sequences that trigger this population’s high specificity T-cell response. The best vaccine candidate was selected through the analysis of tertiary structure validation and molecular docking of each candidate with TLR-4, TLR-8, HLA-A*24:02, and HLA-DRB1*04:05. The selected multi-epitope vaccine combined with the gene encoding the replication machinery that allows the RNA amplification in the host cell. Findings/Results: Seven B-cell and four T-cell epitopes from the protein target were highly antigenic and conserved, non-allergen, non-toxic, and hydrophilic. Tertiary structure validation then determined the best multi-epitope construction with 269 AA in length containing hBD-2 adjuvant and PADRE. Most residues are predicted to be accessible by solvent and show high population coverage (99,26%). Molecular docking analysis demonstrated a stable and strong binding affinity with immune receptors. A recombinant plasmid as the template for mRNA production was constructed by inserting the multi-epitope DNA and non-structural polyprotein 1-4 gene of VEEV, which encodes the RNA replication complex to the cloning site of pcDNA3.1(+). Conclusion and implication: In silico , design of self-amplifying mRNA could be a potential COVID-19 vaccine candidate since its ability to be amplified in the host cell can efficiently reduce the intake doses.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- School of Life Sciences and Technology, Institut Teknologi Bandung, Jalan Ganesa 10, Bandung 40132, Indonesia.
- University Center of Excellence for Nutraceuticals, Bioscience and Biotechnology Research Center, Institut Teknologi Bandung, Jalan Ganesa 10, Bandung 40132, Indonesia.
Zitieren
APA
Claudia, B., Nugrahapraja, H., & Giri-Rachman, E. A. (2024). A multi-epitope self-amplifying mRNA SARS-CoV-2 vaccine design using a reverse vaccinology approach. Research in Pharmaceutical Sciences, 19(5), 520-548. https://doi.org/10.4103/rps.rps_91_23
Vancouver
Claudia B, Nugrahapraja H, Giri-Rachman EA. A multi-epitope self-amplifying mRNA SARS-CoV-2 vaccine design using a reverse vaccinology approach. Research in Pharmaceutical Sciences. 2024;19(5):520-548. doi:10.4103/rps.rps_91_23
BibTeX
@article{Claudia2024,
author = {Claudia, Brigitta and Nugrahapraja, Husna and Giri-Rachman, Ernawati Arifin},
title = {A multi-epitope self-amplifying mRNA SARS-CoV-2 vaccine design using a reverse vaccinology approach},
journal = {Research in Pharmaceutical Sciences},
year = {2024},
volume = {19},
number = {5},
pages = {520--548},
doi = {10.4103/rps.rps_91_23}
}
EUVIMED